Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes

Phase 3

• Conditions: Glucocorticoid Induced Hyperglycemia
• Interventions: Drug: Placebo; Drug: Liraglutide

• Registration Number: NCT02016846
• Lead Sponsor: Rabin Medical Center

Brief Summary

Glucocorticoids therapy exposes the patient to an increased risk for diabetes morbidity. However, there is no proven preventive therapy. GLP-1-RA has shown to improve glucose metabolism in healthy volunteers treated with glucocorticoids. We assume that GLP-1-RA will improve glucose metabolism in patients with high risk for diabetes morbidity, treated with glucocorticoids.

Detailed Description

Not available

Study Timeline

• Status Verified: 2013-12
• Study First Submitted: 2013-12-15
• Study First Submitted QC: 2013-12-15
• Study First Posted: 2013-12-20
• Last Update Submitted: 2013-12-22
• Last Update Posted: 2013-12-24
• Study Start: 2014-01
• Primary Completion: 2015-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Intervention	Liraglutide	Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.

Primary Outcome Measures

Name	Time	Method
Glucose levels 2 hours after 75 gr OGTT	6 weeks

Trial Locations

Locations (1)

Rabin Medical Center, Beilinson Campus; 🇮🇱 Petah Tiqva, Israel